Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

NCT06290466 | Completed Phase 1

• 1 other identifier: FCN-437c-CP-004
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical trial in healthy subjects.In healthy subjects, 300mg and 400mg FCN-437c capsules were taken orally for a single time. C-QTc effect model was used to evaluate the influence of blood concentration on QT interval, and the pharmacokinetic characteristics and safety of FCN-437c were also evaluated.Based on the C-QTc effect model, this study quantitatively analyzed the relationship between ΔΔQTcF and blood concentration, and evaluated the upper limit of 90% bilateral confidence interval of ΔΔQTcF corresponding to the geometric mean of Cmax at clinically relevant dose of FCN-437c capsule. This study plans to set up 2 dose groups, low-dose group 300mg and high-dose group 400mg.Nine healthy subjects were planned to be enrolled in each dose group, with a 2:1 ratio of placebo control. This study was carried out in the order of dose from low to high. After the administration of the low-dose group (300mg) and the safety assessment on the fourth day after administration, the study of the high-dose group (400mg) was decided through comprehensive evaluation.

Conditions

Advanced Breast Cancer

Keywords

QT interval

Outcome Measures

Primary Outcomes (1)

• ΔΔQTcF

  The Cmax geometric mean corresponds to the upper 90% bilateral confidence interval of ΔΔQTcF

  2hours before administration and 48hours and 192hours after administration

Secondary Outcomes (16)

• adverse events

  Trial period to day 21 after administration

• Physical examination

  From 1 day before administration to 21 days after administration

• Axillary temperature

  From 2.0 hours before administration to 21 days after administration

• blood pressure

  From 2.0 hours before administration to 21 days after administration

• pulse

  From 2.0 hours before administration to 21 days after administration

Study Arms (2)

FCN-437c capsule

EXPERIMENTAL

fasting oral, single dose.Specification :100mg

Drug: Low dose group; Drug: High dose group

FCN-437c capsule Placebo

PLACEBO COMPARATOR

fasting oral,single dose.Specification :100mg

Drug: Low dose group; Drug: High dose group

Interventions

Low dose group DRUG

300 mg,single dose.

Also known as: FCN-437c capsule or FCN-437c capsule Placebo

FCN-437c capsule; FCN-437c capsule Placebo

High dose group DRUG

400 mg, single dose.

Also known as: FCN-437c capsule or FCN-437c capsule Placebo

FCN-437c capsule; FCN-437c capsule Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• ．Healthy adult male and female subjects (not less than 1/3 of either sex); 2．18\~45 years old (including boundary values)After bilateral oophorectomy; 3．The body mass index (BMI) should be between 19.0 and 26.0 kg/m2 (including boundary values), and the weight of male subjects should not be less than 50 kg and that of female subjects should not be less than 45 kg; 4．Voluntarily sign informed consent 5．The subjects were able to communicate well with the investigators and complete the test according to protocol.

You may not qualify if:

• Patients who meet any of the following conditions are not allowed to enter this clinical study：
• After a comprehensive physical examination, vital signs, laboratory examination (blood routine, blood biochemistry, coagulation function, urine routine) and other abnormalities and clinical significance;
• Hyperkalemia, hypokalemia, hypermagnesia, hypomagnesemia, hypercalcemia or hypocalcemia, which is abnormal and clinically significant as determined by the investigator;
• Abnormal 12-lead ECG results were clinically significant, QTcF≥450 ms, PR interval ≥200 ms;QRS group duration ≥120ms;
• Hepatitis B surface antigen or hepatitis B core antibody, hepatitis C antibody, HIV antibody or syphilis antibody positive;
• Any drug that inhibits or induces liver drug metabolism enzymes has been used within 30 days prior to the screening period
• Use any drug known to prolong the QT interval within 30 days prior to the screening period
• Use of any prescription, over-the-counter, herbal or food supplements, such as vitamins and calcium supplements, in the 14 days prior to the screening period;
• A history of any clinically serious medical conditions or conditions that the investigator believes may affect the results of the study, including but not limited to circulatory, respiratory, endocrine, nervous, digestive, urinary, or blood, immune, psychiatric, or metabolic disorders;
• Have any conditions that may affect drug absorption, such as gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy, history of inflammatory bowel;
• History of organic heart disease, heart failure, myocardial infarction, angina pectoris, coronary artery bypass grafting, angioplasty, stent stenting, congestive heart failure, uncontrolled hypotension, left ventricular ejection fraction lower than the lower limit of normal location, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, and prolonged QT syndromeOr have symptoms of prolongation QT syndrome and a family history (as shown by genetic evidence or by a close relative who died of sudden cardiac death at a young age);
• Patients who have undergone any surgery within 6 months prior to the screening period;
• Allergy, such as a known history of allergy to two or more substances;Or who may be allergic to the drug or its excipients (e.g. Lactose T80, silica, sodium stearfumarate, etc.) as determined by the investigator;
• Binge drinking or regular drinking in the 6 months preceding the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit =360mL beer or 45 mL spirits with 40% alcohol or 150 mL wine);Or positive alcohol breath test results during the screening period;
• Use of nicotine-containing products from 3 months prior to screening to the period of study participation;

Sponsors & Collaborators

• Ahon Pharmaceutical Co., Ltd.: lead

Study Sites (1)

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

Location

Related Publications (1)

• Zhao L, Sun Y, Yang X, Tian L, Li L, Wang F, Niu X, Diao L, Li H. No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects. Front Pharmacol. 2024 Aug 12;15:1433663. doi: 10.3389/fphar.2024.1433663. eCollection 2024.

  PMID: 39188943 DERIVED

MeSH Terms

Interventions

Population Groups; FCN-437c

Intervention Hierarchy (Ancestors)

Demography; Population Characteristics

Study Officials

• Haiyan Li, MD

  Peking University Third Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 18, 2024
• First Posted: March 4, 2024
• Study Start: November 11, 2022
• Primary Completion: February 8, 2023
• Study Completion: February 8, 2023
• Last Updated: March 4, 2024

Record last verified: 2024-02

Locations

CN (1)